Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study
详细信息 查看全文
- 作者：Hassan Seddik (1)
Samir Ahid (2) (3) (4)
Tarek El Adioui (1)
Fatim-Zohra El Hamdi (1)
Mohammed Hassar (2)
Redouane Abouqal (3)
Yahia Cherrah (2)
Ahmed Benkirane (1) - 关键词：Sequential therapy ; Standard triple ; drug ; Helicobacter pylori infection ; 13C ; Urea breath test
- 刊名：European Journal of Clinical Pharmacology
- 出版年：2013
- 出版时间：September 2013
- 年：2013
- 卷：69
- 期：9
- 页码：1709-1715
- 全文大小：175KB
- 参考文献：1. Graham DY, Lu H, Yamaoka Y (2007) A report card to grade / Helicobacter pylori therapy. Helicobacter 12:275-78 CrossRef
2. Malfertheiner P, Megraud F, O’Morain C et al (1997) Current European concepts in the management of / Helicobacter pylori infection–the Maastricht consensus report. The European / Helicobacter pylori study group (EHPSG). Eur J Gastroenterol Hepatol 9:1- CrossRef
3. Sasaki M, Ogasawara N, Utsumi K et al (2010) Changes in 12-year first-line eradication rate of / Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr 47:53-8 CrossRef
4. Laurent J, Megraud F, Flejou JF et al (2001) A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of / Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 15:1787-793 CrossRef
5. Iacopini F, Crispino P, Paoluzi OA et al (2005) One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for / Helicobacter pylori eradication. Dig Liver Dis 37:571-76 CrossRef
6. Laheij RJ, Rossum LG, Jansen JB et al (1999) Evaluation of treatment regimens to cure / Helicobacter pylori infection—a meta-analysis. Aliment Pharmacol Ther 13:857-64 CrossRef
7. Malfertheiner P, Megraud F, O’Morain C et al (2007) Current concepts in the management of / Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007(56):772-81 CrossRef
8. Megraud F (2007) / Helicobacter pylori and antibiotic resistance. Gut 56(11):1502 CrossRef
9. Gisbert JP, Calvet X, O’Connor A et al (2010) Sequential therapy for / Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 44:313-25 CrossRef
10. Vaira D, Zullo A, Vakil N et al (2007) Sequential therapy versus standard triple-drug therapy for / Helicobacter pylori eradication: a randomized trial. Ann Intern Med 146:556-63 CrossRef
11. Zullo A, Rinaldi V, Winn S et al (2000) A new highly effective short-term therapy schedule for / Helicobacter pylori eradication. Aliment Pharmacol Ther 14:715-18 CrossRef
12. Sánchez-Delgado J, Calvet X, Bujanda L et al (2008) Ten-day sequential treatment for / Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 103(9):2220-223 CrossRef
13. Sirimontaporn N, Thong-Ngam D, Tumwasorn S et al (2010) Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol 105(5):1071-075 CrossRef
14. Kwon JH, Lee DH, Song BJ et al (2010) Ten-day sequential therapy as first-line treatment for / Helicobacter pylori infection in Korea: a retrospective study. Helicobacter 15(2):148-53 CrossRef
15. Jafri NS, Hornung CA, Howden CW (2008) Meta-analysis: sequential therapy appears superior to standard therapy for / Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 148:923-31 CrossRef
16. Malfertheiner P, Megraud F, O’Morain CA et al (2012) European Helicobacter Study Group. Management of / Helicobacter pylori infection. The Maastricht IV/Florence Consensus Report. Gut 61(5):646-64 CrossRef
17. Dixon MF, Genta RM, Yardley JH et al (1996) Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston, 1994. Am J Surg Pathol 20:1161-181 CrossRef
18. Nishizawa T, Suzuki H, Suzuki M et al (2012) Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line / Helicobacter pylori eradication therapy. J Clin Nutr Biochem 51(2):114-16 CrossRef
19. Oh HS, Lee DH, Seo JY et al (2012) Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 27(3):504-09 CrossRef
20. Basu PP, Rayapudi K, Pacana T et al (2011) Randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of / Helicobacter pylori. Am J Gastroenterol 106(11):1970-975 CrossRef
21. Bigard MA, Delchier JC, Riachi G et al (1998) One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of / Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 12:383-88 CrossRef
22. Perri F, Villani MR, Festa V et al (2001) Predictors of failure of / Helicobacter pylori eradication with the standard ‘Maastricht triple therapy- Aliment Pharmacol Ther 15:1023-029 CrossRef
23. Kadayifci A, Buyukhatipoglu H, Cemil Savas M et al (2006) / Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 28:1960-966 CrossRef
24. Vakil N, Lanza F, Schwartz H et al (2004) Seven-day therapy for / Helicobacter pyloriin the United States. Aliment Pharmacol Ther 20:99-07 CrossRef
25. Graham DY, Fischbach L (2010) / Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59:1143-153 CrossRef
26. Zullo A, Vaira D, Vakil N et al (2003) High eradication rates of / Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 17:719-26 CrossRef
27. Zullo A, De Francesco V, Hassan C et al (2007) The sequential therapy regimen for / Helicobacter pylori eradication: a pooled-data analysis. Gut 56:1353-357 CrossRef
28. Nadir I, Yonem O, Ozin Y et al (2011) Comparison of two different treatment protocols in / Helicobacter pylori eradication. South Med J 104:102-05 CrossRef
29. Glupczynski Y, Megraud F, Lopez-Brea M et al (2001) European multicentre survey of in vitro antimicrobial resistance in / Helicobacter pylori. Eur J Clin Microbiol Infect Dis 20:820-23 CrossRef
30. Megraud F, Coenen S, Versporten A et al (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62:34-2 CrossRef
31. Kim JM, Kim JS, Jung HC et al (2004) Distribution of antibiotic MICs for / Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 48:4843-847 CrossRef
32. Bang SY, Han DS, Eun CS et al (2007) Changing patterns of antibiotic resistance of / Helicobacter pylori in patients with peptic ulcer disease. Korean J Gastroenterol 50:356-62
33. De Francesco V, Giorgio F, Hassan C et al (2010) Worldwide / H. / pylori antibiotic resistance: a systematic review. J Gastrointest Liver Dis 19(4):409-14
34. Alaoui S, Mahmoud M, Amarti A et al. Clarithromycin resistance of / Helicobacter pylori: prospective study among patients in the northern center of Morocco. Abstract available at:http://www.snfge.asso.fr/01-Bibliotheque/0A-Resumes-JFHOD/2012/6511.html. Accessed 5 Sept 2012
35. Uygun A, Kadayifci A, Safali M et al (2007) The efficacy of bismuth containing quadruple therapy as a first-line treatment option for / Helicobacter pylori. J Dig Dis 8(4):211-15 CrossRef
36. Ma J, Liu W, Zhang L et al (2010) A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate / Helicobacter pylori infection; a pilot study for the large Linqu County trial. Eur J Gastroenterol Hepatol 22(5):597-01 CrossRef
37. Salazar CO, Cardenas VM, Reddy RK et al (2012) Greater than 95% success with 14-day Bismuth Quadruple anti- / Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter 17(5):382-89 CrossRef
38. Malfertheiner P, Bazzoli F, Delchier JC et al (2011) / Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazoleand tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377:905-13 CrossRef
39. Yanai A, Sakamoto K, Akanuma M et al (2012) Non-bismuth quadruple therapy for first-line / Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 3(1):1- CrossRef
40. Essa AS, Kramer JR, Graham DY et al (2009) Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy-versus triple therapy / for Helicobacter pylori eradication. Helicobacter 14:109-18 CrossRef
41. Gisbert JP, Calvet X (2011) Review article: non-bismuth quadruple (concomitant) therapy for eradication of / Helicobater pylori. Aliment Pharmacol Ther 34:604-17 CrossRef
42. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M et al (2010) Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for / Helicobacter pylori eradication. Aliment Pharmacol Ther 31(10):1077-084
43. Gisbert JP, Morena F (2006) Systematic review and meta-analysis: levofloxacin-based rescue regimens after / Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23:35-4 CrossRef
44. Graham DY, Shiotani A (2008) New concepts of resistance in the treatment of / Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 5:321-31 CrossRef
45. Li Y, Huang X, Yao L et al (2010) Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent / Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 122:413-22 CrossRef
46. De Francesco V, Zullo A, Hassan C et al (2001) Two new treatment regimens for / Helicobacter pylori eradication: a randomised study. Dig Liver Dis 33:676-79 CrossRef
47. Hassan C, De Francesco V, Zullo A et al (2003) Sequential treatment for / Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 18:641-46 CrossRef
48. Paoluzi OA, Visconti E, Andrei F et al (2010) Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating / Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol 44(4):261-66 CrossRef
49. Sirimontaporn N, Thong-Ngam D, Tumwasorn S et al (2010) Ten-day sequential therapy of / Helicobacter pylori infection in Thailand. Am J Gastroenterol 105:1071-075 CrossRef
50. Park HG, Jung MK, Jung JT et al (2012) Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standardtriple therapy for / Helicobacter pylori infection in na?ve patients. Aliment Pharmacol Ther 35(1):56-5 CrossRef
51. Zhou YQ, Xu L, Wang BF et al. (2012) Modified sequential therapy. Regimen versus conventional triple therapy for / Helicobacter pylori eradication in duodenal ulcer patients in China: a multicenter clinical comparative study. Gastroenterol Res Pract:405425. Epub 2011 Nov 21. doi:10.1155/2012/405425
52. Gasparetto M, Pescarin M, Guariso G (2012) / Helicobacter pylori eradication therapy: current availabilities. ISRN Gastroenterol:186734. Epub 2012 Jul 29. doi:10.5402/2012/186734
53. Tong JL, Ran ZH, Shen J et al (2009) Sequential therapy vs. standard triple therapies for / Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 34:41-3 CrossRef - 作者单位：Hassan Seddik (1)
Samir Ahid (2) (3) (4)
Tarek El Adioui (1)
Fatim-Zohra El Hamdi (1)
Mohammed Hassar (2)
Redouane Abouqal (3)
Yahia Cherrah (2)
Ahmed Benkirane (1)
1. Department of Gastroenterology II, Mohammed V Teaching Military Hospital, Rabat, Morocco
2. Pharmacoepidemiology and Pharmacoeconomics Research Team, Medical and Pharmacy School, Mohammed V–Souissi University, Rabat, Morocco
3. Biostatistics, Clinical and Epidemiological Research Laboratory, Medical and Pharmacy School, Mohammed V–Souissi University, Rabat, Morocco
4. Laboratory of Pharmacology and Toxicology, Medical and Pharmacy School–Rabat, Avenue Mohammed Belarabi Elalaoui, BP 6203, Rabat, 10100, Morocco
文摘
Purpose Eradication rates following standard triple therapy for Helicobacter pylori infection are declining. Recent studies, conducted in a number of countries, have shown that sequential therapy for H. pylori infection yields high cure rates. Aim To compare the efficacy and tolerability of a sequential regimen as a first-line treatment of H. pylori infection with a standard triple treatment regime in Morocco. Methods A total of 281 naive H. pylori-infected patients, confirmed by histological examination, were assigned randomly to one of two treatment groups: standard triple therapy [omeprazole (20?mg bid) + amoxicillin (1?g bid) + clarithromycin (500?mg bid) for 7?days] or sequential therapy [omeprazole (20?mg bid) + amoxicillin (1?g bid) for 5?days, followed by omeprazole (20?mg bid) + tinidazole (500?mg bid) + clarithromycin (500?mg bid) for an additional 5?days]. H. pylori eradication was checked 4-?weeks after treatment initiation by using a 13C-urea breath test. Compliance and adverse events were assessed. Results The two groups did not differ significantly in gender, age, previous disease history, endoscopic and histological features and smoking. The intention-to-treat and per-protocol eradication rates were 65.9 and 71?% in the standard triple therapy group, and 82.8 and 89.9?% in the sequential therapy group, respectively. The eradication rate was significantly higher in the sequential therapy group than in the standard triple therapy group (p-lt;-.001), There was no statistically significant difference in compliance (97.5? vs. 96.3?%) and incidence of side-effects (27.5 vs. 27.9?%) between the two groups. Conclusions Based on our results, we conclude that for eradication of H. pylori infection, the 10-day sequential therapy is more effective than the standard triple therapy and is equally tolerated. These results confirm those of other studies in other countries.